Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generic pharmaceutical firm Mylan has priced its concurrent public offerings of 1.86 million shares of 6.50% mandatory convertible preferred stock at $1,000 per share, and 53.5 million shares of common stock at $14 per share, pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission.
Subscribe to our email newsletter
The underwriters have options to purchase approximately 279,000 additional shares of preferred stock and approximately 8.025 million shares of common stock, in each case to cover over-allotments, if any. These offerings are separate public offerings by means of separate prospectus supplements and the closing of each offering is not contingent on the other.
The preferred stock will pay, when declared by the board of directors, dividends at a rate of 6.50% percent per annum on the liquidation preference of $1,000 per share, payable quarterly in arrears in cash, shares of Mylan common stock or a combination thereof at Mylan’s election. The first dividend date will be February 15, 2008.
Each share of preferred stock will automatically convert on November 15, 2010, into between approximately 58.5480 shares and 71.4286 shares of MYL common stock. The conversion rate will be subject to anti-dilution adjustments in certain circumstances. Holders may elect to convert at any time at the minimum conversion rate of 58.5480 shares of common stock for each share of preferred stock. The preferred stock has been approved for listing on the New York Stock Exchange, subject to issuance. The ticker symbol for this security will be MYLPrA.